About Us
Kinex Pharmaceuticals is developing next generation anti-cancer drugs that target the molecular basis of disease. The Company uses a proprietary technology platform to generate compounds that inhibit the Protein Kinase and Phosphatase family of proteins.
Protein kinases and phosphatases are intimately involved in transmitting signals across the cell membrane. They control critical events such as cell proliferation, cell movement and cell death. Abnormally elevated activity of both protein kinases and phosphatases is associated with a number of diseases, including cancer. Inhibitors of these target proteins have proven to be useful drugs in fighting cancer.
Mimetica™ is Kinex Pharmaceuticals’ patented technology for generating small molecule inhibitors of kinases and phosphatases that bind in the substrate pocket. This technology allows one to construct non-peptide inhibitors, in a modular fashion, utilizing protein structural and/or peptide substrate specificity information. The resulting inhibitors are systematically increased in complexity, using combinatorial chemistry and high-throughput screening technologies, until the desired level of potency, specificity, and in vivo properties are obtained. Mimetica™ generates small molecule inhibitors possessing "drug-like" physical properties suitable for oral therapeutic agents.
Protein kinases and phosphatases are intimately involved in transmitting signals across the cell membrane. They control critical events such as cell proliferation, cell movement and cell death. Abnormally elevated activity of both protein kinases and phosphatases is associated with a number of diseases, including cancer. Inhibitors of these target proteins have proven to be useful drugs in fighting cancer.
Mimetica™ is Kinex Pharmaceuticals’ patented technology for generating small molecule inhibitors of kinases and phosphatases that bind in the substrate pocket. This technology allows one to construct non-peptide inhibitors, in a modular fashion, utilizing protein structural and/or peptide substrate specificity information. The resulting inhibitors are systematically increased in complexity, using combinatorial chemistry and high-throughput screening technologies, until the desired level of potency, specificity, and in vivo properties are obtained. Mimetica™ generates small molecule inhibitors possessing "drug-like" physical properties suitable for oral therapeutic agents.